Needham & Company
-
Adamas to Present at the 16th Annual Needham Healthcare Conference
-
Needham & Company Reiterates Bullish View on Adamas (ADMS) as FDA Approves Namzaric Label Expansion
-
Adamas Pharmaceuticals to Present at Two Upcoming Healthcare Conferences
-
Adamas Pharmaceuticals (ADMS) PT Raised to $38 at Needham & Company
-
Adamas Pharmaceuticals to Present at 2015 Needham Healthcare Conference
-
Adamas Pharmaceuticals to Present at 2015 Needham Healthcare Conference
-
Adamas Pharmaceuticals (ADMS) Bullish Stance Reiterated at Needham & Company as ADS-5102 Moves Into Phase III
-
Needham & Company Starts Adamas Pharmaceuticals (ADMS) at Buy
-
Adamas Pharmaceuticals (ADMS) IPO Opens Higher
-
Adamas Pharmaceuticals (ADMS) IPO Prices at $16, Low End of Range

